The order includes a small quantity of flow plates and has limited impact on cash flow and earnings. Despite its modest size, the deal is strategically significant as it confirms that the project is now entering a production phase, with the goal of gradually increasing volumes.

"The agreement is a confirmation that the market is starting to move in the right direction, despite long lead times. Together with the customer, we have developed a flow plate that meets high standards for functionality and quality, while also being optimized for efficient production. We are now beginning to reap the rewards of our efforts-and in this project, we are doing so according to plan," says Daniel Vallin, CEO of Cell Impact.